Department of Anaesthesiology, Intensive Care and Pain Medicine, Universitätsklinikum Münster, Münster, Germany.
Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany.
BMJ Open. 2021 Dec 30;11(12):e055705. doi: 10.1136/bmjopen-2021-055705.
More than 300 million surgical procedures are performed each year. Acute kidney injury (AKI) is a common complication after major surgery and is associated with adverse short-term and long-term outcomes. However, there is a large variation in the incidence of reported AKI rates. The establishment of an accurate epidemiology of surgery-associated AKI is important for healthcare policy, quality initiatives, clinical trials, as well as for improving guidelines. The objective of the Epidemiology of Surgery-associated Acute Kidney Injury (EPIS-AKI) trial is to prospectively evaluate the epidemiology of AKI after major surgery using the latest Kidney Disease: Improving Global Outcomes (KDIGO) consensus definition of AKI.
EPIS-AKI is an international prospective, observational, multicentre cohort study including 10 000 patients undergoing major surgery who are subsequently admitted to the ICU or a similar high dependency unit. The primary endpoint is the incidence of AKI within 72 hours after surgery according to the KDIGO criteria. Secondary endpoints include use of renal replacement therapy (RRT), mortality during ICU and hospital stay, length of ICU and hospital stay and major adverse kidney events (combined endpoint consisting of persistent renal dysfunction, RRT and mortality) at day 90. Further, we will evaluate preoperative and intraoperative risk factors affecting the incidence of postoperative AKI. In an add-on analysis, we will assess urinary biomarkers for early detection of AKI.
EPIS-AKI has been approved by the leading Ethics Committee of the Medical Council North Rhine-Westphalia, of the Westphalian Wilhelms-University Münster and the corresponding Ethics Committee at each participating site. Results will be disseminated widely and published in peer-reviewed journals, presented at conferences and used to design further AKI-related trials.
NCT04165369.
每年有超过 3 亿例手术。急性肾损伤(AKI)是大手术后常见的并发症,并与不良的短期和长期结局相关。然而,报告的 AKI 发生率存在很大差异。建立准确的手术相关 AKI 流行病学对于医疗保健政策、质量倡议、临床试验以及改善指南都非常重要。手术相关急性肾损伤的流行病学(EPIS-AKI)试验的目的是使用最新的肾脏病:改善全球预后(KDIGO)AKI 共识定义,前瞻性评估大手术后 AKI 的流行病学。
EPIS-AKI 是一项国际性的前瞻性、观察性、多中心队列研究,纳入了 10000 例接受大手术的患者,这些患者随后被收入 ICU 或类似的高依赖病房。主要终点是根据 KDIGO 标准术后 72 小时内 AKI 的发生率。次要终点包括肾脏替代治疗(RRT)的使用、ICU 和住院期间的死亡率、ICU 和住院时间的长短以及第 90 天的主要不良肾脏事件(由持续肾功能障碍、RRT 和死亡率组成的联合终点)。此外,我们将评估影响术后 AKI 发生率的术前和术中危险因素。在附加分析中,我们将评估尿生物标志物对 AKI 的早期检测。
EPIS-AKI 已获得北莱茵-威斯特法伦州医学委员会、明斯特市威斯特伐利亚威廉姆斯大学的领导伦理委员会以及每个参与站点的相应伦理委员会的批准。结果将广泛传播和发表在同行评议的期刊上,在会议上展示,并用于设计进一步的 AKI 相关试验。
NCT04165369。